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Noroviruses (NoVs) are considered to be a major cause of acute nonbacterial gastroenteritis in humans. The
NoV genus is genetically diverse, and genotype GII.4 has been most commonly identified worldwide in recent
years. In this study we analyzed the complete capsid gene of NoV strains belonging to the less prevalent
genotype GII.2. We compared a total of 36 complete capsid sequences of GII.2 sequences obtained from the
GenBank (n  5) and from outbreaks or sporadic cases that occurred in The Netherlands (n  10) and in
Osaka City, Japan (n  21), between 1976 and 2005. Alignment of all capsid sequences did not show fixation
of amino acid substitutions over time as an indication for genetic drift. In contrast, when strains previously
recognized as recombinants were excluded from the alignment, genetic drift was observed. Substitutions were
found at five informative sites (two in the P1 subdomain and three in the P2 subdomain), segregating strains
into five genetic groups (1994 to 1997, 1999 to 2000, 2001 to 2003, 2004, and 2005). Only one amino acid position
changed consistently between each group (position 345). Homology modeling of the GII.2 capsid protein
showed that the five amino acids were located on the surface of the capsid and close to each other at the
interface of two monomers. The data suggest that these changes were induced by selective pressure, driving
virus evolution. Remarkably, this was observed only for nonrecombinant genomes, suggesting differences in
behavior with recombinant strains.
Noroviruses (NoVs) are an important cause of acute non-
bacterial gastroenteritis in adults and children worldwide (13).
NoVs are members of the family Caliciviridae, having a posi-
tive-sense single-stranded RNA genome. Their genome is or-
ganized into three open reading frames (ORFs). ORF1 en-
codes nonstructural proteins including the RNA-dependent
RNA polymerase (RdRp), ORF2 encodes a major structural
capsid protein including a shell (S) domain and a protruding
(P) domain, and ORF3 encodes a minor structural protein (13,
18, 41). The S domain forms the inner part (shell) of the viral
capsid, and the P domain forms the arch-like structures that
protrude from the virion. The P domain is further divided into
P1 and P2 subdomains that correspond to the sides and the top
of the arch-like capsomeres, respectively (13, 31).
Based on the genetic analysis of the RdRp and capsid re-
gions, human NoVs can be divided into three genogroups (Gs),
GI, GII, and GIV (2, 14, 39), which further segregate into
distinct lineages called genotypes (2, 20, 36, 37). Recently,
Kageyama et al. (20) proposed that at least 31 genotypes could
be distinguished within GI and GII. The GII.4 genotype, which
is represented by the Lordsdale/93/UK strain, has been the
most commonly identified genotype worldwide in recent years.
Genetic characterization of strains belonging to this genotype
have shown a sequence of variants that have arisen over time,
suggesting that rapid genetic evolution of GII.4 NoVs may in
part explain their successful spread and impact on people of all
ages (5, 9, 27, 29, 30, 33, 40).
Viruses belonging to other NoV genotypes are found less
consistently, causing sporadic outbreaks or temporary epidem-
ics in a limited geographic region or time period (5, 17, 23, 26).
As a result, far less is known about the population structure of
these variants (28). The genetic analysis of other genotype
NoVs excluding GII.4 will improve our understanding of ge-
netic evolution and its relevance for the epidemiology of NoVs.
During the spring of 2004, an epidemic of GII.2 NoV (which
is represented by the Melksham/94/UK strain [Melksham])
occurred in Osaka City, Japan. Our previous study of this
regional epidemic described the molecular epidemiology of
these GII.2 strains (17). Here, we describe the genetic charac-
terization of GII.2 strains from those outbreaks in comparison
with viruses detected over a 12-year period in the GenBank,
The Netherlands, and Japan.
MATERIALS AND METHODS
GII.2 strains. A total of 36 NoV strains that had been characterized as GII.2
genotype were used for this study (Table 1). The capsid sequence data for five
GII.2 strains were obtained from the GenBank. Of these, the Melksham strain
and the Chesterfield/434/1997/US strain (11, 29) have been characterized as
belonging to the GII.2 genotype on the basis of RdRp as well as capsid regions.
The Snow Mountain/76/US strain has been characterized as a recombinant NoV,
with a distinct (non-GII.2) RdRp region and a GII.2 capsid region (4, 16). The
other two strains from the GenBank (Ina/02/JP and Buds/02/US) were charac-
terized as GII.2 genotype on the basis of the capsid region, but their sequences
of the RdRp region were unknown. The capsid sequence data of Buds/02/US
strain lacked the first 6 nucleotides (nt) from the 5 end of the capsid gene.
Twenty-one GII.2 strains were obtained from outbreaks or sporadic cases de-
tected in Osaka City, Japan, between April 1996 and March 2005. These were 21
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of the 23 GII.2 strains identified during a 9-year study period out of a total of 238
outbreaks and 200 sporadic cases of NoV infection. From the genetic analysis
across the junction between the RdRp and the capsid regions, 6 of these 21 GII.2
strains have been characterized as recombinants, which have non-GII.2 RdRp
regions and GII.2 capsid regions (Fig. 1) (17).
The strains from The Netherlands were collected from a 12-year study period.
Between 1994 and 2005, GII.2 NoVs were detected in 13 (1.7%) out of 745
NoV-associated outbreaks and three sporadic cases in The Netherlands. Initially,
these GII.2 NoVs were characterized by the comparison of sequences in the
RdRp region (Fig. 1). The detection method and criteria for genotyping at the
RdRp region have been previously described (8, 36). The complete capsid genes
of 10 strains from eight outbreaks and two sporadic cases were amplified by
reverse transcription-PCR (RT-PCR) and were used for this analysis.
Amplification and sequencing for the complete capsid gene of GII.2 strains.
Viral RNA was extracted from stool suspensions by using a QIAamp viral RNA
Mini kit (Qiagen, Hilden, Germany). RT-PCR was carried out with the reaction
mixtures and enzymes as previously described (8). RT was performed at 42°C for
2 to 3 h with reverse primer, N235Rex (17), and enzyme was inactivated at 95°C
for 5 min. PCR was performed using several pairs of PCR primers (Table 2) with
a GeneAmp PCR system 9700 (Applied Biosystems, Foster City, CA) under the
following conditions: denaturation at 95°C for 1 min; 40 cycles of 95°C for 15 s,
50°C for 30 s, and 72°C for 1 min; and a final cycle of incubation at 72°C for 5
min. When a PCR failed to produce strong products, we performed nested PCR.
The amplified fragments were sequenced directly with a Big Dye terminator cycle
sequencing kit and ABI 3700 sequencer (Applied Biosystems, Foster City, CA).
The nucleotide sequences were determined in both orientations using the PCR
primers. DNA sequences were edited using SeqManII (DNAStar Inc., Konstanz,
Germany).
Sequence analysis. Nucleotide or amino acid sequence alignments were per-
formed with BioEdit (version 7.052) (15), Clustal X (version 1.81) (35), or
MUSCLE (version 3.51) (10). The extraction of the informative sites from
nucleotide or amino acid sequence alignments was performed with ProSeq (ver-
sion 2.91) (12). The rate of change for different domains was compared using
chi-square statistics. In this analysis, a site was designated as an informative site
when at least two strains had an identical amino acid in the alignment that
differed from the other sequences. A phylogenetic tree with 1,000 bootstrap
replications was constructed by the neighbor-joining method, and the genetic
distances were calculated according to the Kimura two-parameter method (21).
We performed additional phylogenetic analysis by the Bayesian method using
MrBayes (version 3.1.2) (32). Location of specific domains of the GII.2 NoV
capsid gene was done according to Chen et al. (7). For computational predictions
of the structure of the GII.2 NoV capsid protein, we used the X-ray crystal
structures of the capsid protein of Norwalk/68/US (GI.1 genotype, Protein Data
Bank identifier [PDB ID] 1IHM, consisting of a complete trimer) (31) and
VA387/98/US (GII.4 genotype, PDB ID 2OBR, consisting of only a monomeric
P domain) (6) as templates to build homology models. The sequence alignments
for the structure and the three-dimensional (3D) models for GII.2 NoV capsid
proteins were made by using the WHAT IF program (38) and the 3D-Jigsaw (3)
TABLE 1. GII.2 NoV strains used in this study
Source Strain (abbreviation)a RdRp sequencetypeb Accession no. Note
c
GenBank Snow Mountain/76/US (SM) GII-NA AY134748
Melksham/94/UK (Melksham) GII.2 X81879
Chesterfield/434/97/US (CF434) GII.2 AY054300
Ina/02/JP (Ina) Unknown AB195225
Buds/02/US (Buds) Unknown AY660568
Osaka City, Japan OC97049/97/JP (97049) GII-NA AB279553 O
OC01243/01/JP (01243) GII-NA AB279554 O
OC02012/02/JP (02012) GII.2 AB279555 O
OC02022/02/JP (02022) GII-NA AB279556 O
OCS020289/02/JP (S020289) GII.b AB279570 S
OC04038/04/JP (04038)d GII.2 AB279557 O*
OC04042/04/JP (04042)d GII.2 AB279558 O*
OC04043/04/JP (04043)d GII.2 AB279559 O*
OCS030697/04/JP (S030697)d GII.2 AB279571 S*
OC04056-1/04/JP (04056-1)d GII.2 AB279560 O*
OC04056-2/04/JP (04056-2)d GII.2 AB279561 O*
OC04059/04/JP (04059) GII.2 AB279562 O*
OCS040035/04/JP (S040035) GII.2 AB279572 S*
OC04067/04/JP (04067)d GII.2 AB279563 O*
OC04071/04/JP (04071) GII.2 AB279564 O*
OC04073/04/JP (04073) GII.2 AB279565 O*
OC04075/04/JP (04075) GII.2 AB279566 O*
OC04076/04/JP (04076)d GII.2 AB279567 O*
OCS040100/04/JP (S040100) GII.2 AB279573 S*
OC04169/04/JP (04169) GII-NA AB279568 O
OC05010/05/JP (05010) GII.b AB279569 O
The Netherlands Sensor99-191/99/NL (S99-191) GII.2 AB281081 S
OB0037-246/00/NL (OB0037) GII.2 AB281082 O
OB0048-318/00/NL (OB0048) GII.2 AB281083 S
OB0115-195/01/NL (OB0115) GII.2 AB281084 O
EP0125-006/01/NL (EP0125) GII.2 AB281085 O
EP0207-001/02/NL (EP0207) GII.2 AB281086 O
EP0239-001/02/NL (EP0239) GII.2 AB281087 O
OB0371-459/03/NL (OB0371) GII.2 AB281088 O
OB0528-158/05NL (OB0528) GII.2 AB281089 O
OB0587-470/05/NL (OB0587) GII.2 AB281090 O
a NoV strains are arranged in chronology of detection from top (oldest) to bottom (most recent) for each source.
b NA, not assigned.
c O, outbreak; S, sporadic case; *, spring epidemic in 2004.
d These strains have identical amino acid sequences in the complete capsid gene and only one strain (OC04038/04/JP) has been used for long-term genetic analysis.
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and EsyPred3D (25) servers. WHAT IF could not model residues 342, 344, and
345 based on the Norwalk/68/US capsid protein template (PDB ID 1IHM); as
they are present in an inserted loop of the P2 subdomain relative to the template
structure, but they are predicted to be in the same position as in the 3D model
based on the GII.4 genotype capsid protein template (PDB ID 2OBR). A dimer
of the GII.2 NoV capsid protein was modeled by superimposing two predicted
monomers onto the trimeric template of the Norwalk/68/US capsid protein. The
3D models were visualized by the YASARA view program (version 6.813, http:
//www.yasara.org/) (24).
Nucleotide sequence accession numbers. The nucleotide sequences deter-
mined in this study have been deposited in the DDBJ/EMBL/GenBank with the
accession numbers AB281081 to AB281090 (Table 1).
RESULTS
Capsid gene sequence analysis of GII.2 strains collected
over 30 years. Sequence data from a total of 36 GII.2 strains
showed that the capsid gene was 1,629 nt long and coded for a
protein of 542 amino acids. There were no deletions or inser-
tions in the capsid gene among these strains collected over a
30-year period. Sequence comparison showed 83.6% nucle-
otide and 93.5% amino acid identities among these GII.2
strains. The phylogenetic tree based on the 1,629 nucleotide
sequences of the complete capsid gene confirmed that all
strains were characterized as GII.2 genotype (Fig. 2).
Genetic analysis of GII.2 strains from a regional outbreak
in Japan in the spring of 2004. Of the 21 GII.2 strains detected
in Osaka City, Japan, 14 strains were detected in samples from
cases in outbreaks or sporadic cases in the spring epidemic
between March and May 2004 (Table 1). These strains were
closely related to each other (99.2% nucleotide and 99.1%
amino acid identities). To find out if these viruses changed
genetically during circulation in the community for a short
period of time (about 3 months), the complete nucleotide and
amino acid sequences of the capsid gene from these 14 GII.2
strains were compared. A total of 45 nucleotide substitutions
were observed (Table 3). The majority were third-base position
changes (77.8%) and synonymous substitutions (82.2%). These
nucleotide changes resulted in amino acid changes in eight
codons, five of which were located in the P2 subdomain. In the
alignment of the spring epidemic strains over the 3-month
period, of the 45 nucleotide substitutions, only one nucleotide
position was fixed (nt 594 in the S domain) at the end of this
epidemic. This did not result in an amino acid change. All
amino acid changes were sporadic. Eight of the 14 strains had
an identical amino acid sequences (Table 1). Of these, strain
04038 was used for further genetic analysis.
Genetic analysis of all GII.2 strains collected between 1976
and 2005. The nucleotide and amino acid sequences of the
complete capsid genes were compared for 29 GII.2 strains
collected between 1975 and 2005 (30 years), excluding 7 GII.2
strains detected in Osaka City with identical amino acid se-
quences (10 strains from The Netherlands, 14 from Osaka City,
and 5 from GenBank). A total of 488 nucleotide changes were
observed (Table 4). Again, the majority of these were third-
base changes (83.8%) and synonymous (85.9%). In total, 59
nucleotide changes resulted in amino acid changes (34 in the
P2 subdomain) (Table 4). Twenty-five of these were informa-
tive changes (19 in the P2 subdomain), but none appeared to
be fixed in the genome over time. Of the 25 informative sites,
the amino acid position 345 was the most variable (Fig. 3).
Nevertheless, statistical analysis showed a significantly higher
rate of mutation in the P2 subdomain than in P1 and S, sug-
gesting selective pressure (P  0.0018, chi-square 5.63; and
P  0.0001, chi-square 12.9).
Genetic analysis of Melksham-like strains detected between
1994 and 2005. In order to understand the apparent discrep-
ancy between selective changes in the P2 subdomain and the
absence of fixation of these mutations, we repeated our anal-
FIG. 1. Phylogenetic analysis of partial RdRp gene sequences of GII.2 NoV strains by the neighbor-joining method (A) and the Bayesian
method (B). The genotypes at the RdRp regions that are not assigned numbers are represented as GII-NA. The scale indicates the number of
substitutions per site. Reference strains of NoV used in this analysis are given in italics. (A) The bootstrap values are indicated on each branch.
(B) Tree topology was evaluated on the basis of 1,500,000 generations. The posterior probabilities are indicated on each branch (0.95 of the
posterior probability means that the branch has high credibility). The GenBank accession numbers of the additional reference strains used in this
analysis are as follows: Hokkaido/133/03/JP, AB212306; Lordsdale/93/UK, X86557; MOH/99/HU, AF397256; Norwalk/68/US, M87661; Pont de
Roide 673/04/FR, AY682549; Saitama U1, AB039775; Toronto/93/CA, U02030. For strain abbreviations, see Table 1.
TABLE 2. Primers used to amplify the capsid gene of GII.2 NoV strains
Primer Sequence (5 to 3)a Polarity Location (nt) Reference or source
COG2F CARGARBCNATGTTYAGRTGGATGAG  5003b 19
G2SKF CNTGGGAGGGCGATCGCAA  5058b 22
G2SKR CCRCCNGCATRHCCRTTRTACAT  5401b 22
N235Rex GCWANRAAAGCTCCWGCCAT  6273b 17
MKcap508-524F CAGAAAGATGATCCCAA  508c This study
MKcap524-508R TTGGGATCATCTTTCTG  524c This study
MKcap662-649R TCCACTGTTGGTGG  662c This study
MKcap1109-1125F TGGGTCAGATTCAAATT  1109c This study
MKcap1125-1109R AATTTGAATCTGACCCA  1125c This study
MKcap1304-1290R AAGAGCAGGCGCTCC  1304c This study
MK35R CAAAAGCTCCAGCCAT  1644c This study
a Abbreviations for residues in boldface are as follows: B, not A; H, not G. In addition, N is A, C, G, or T; R is A or G; W is A or T; Y is C or T.
b Location of the 5 end of the primer corresponding to the nucleotide position of Lordsdale/93/UK (X86557).
c Location of the 5 end of the primer corresponding to the nucleotide position of ORF2 and ORF3 of Melksham/94/UK (X81879).
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FIG. 2. Phylogenetic analysis of complete capsid gene sequences of GII.2 NoV strains by the neighbor-joining method (A) and the Bayesian
method (B). Melksham-like strains, which have a matching (GII.2) RdRp sequence, are shown in boldface. Asterisks indicate the GII.2 strains that
have different () or unknown () genotypes in the RdRp region. The scale indicates the number of substitutions per site. (A) The bootstrap values
are indicated on each branch. (B) Tree topology was evaluated on the basis of 500,000 generations. The posterior probabilities are indicated on
each branch. The GenBank accession numbers of the additional reference strains used in this analysis are as follows: Hawaii/71/US, U07611;
Hillingdon/90/UK, AJ277607; Lordsdale/93/UK, X86557; Norwalk/68/US, M87661; Toronto/93/CA, U02030. For strain abbreviations, see Table 1.
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ysis after removing recombinant genomes from the alignment
(Table 5) (nucleotide and amino acid sequences of the com-
plete capsid gene from 20 Melksham-like strains: 10 strains
from The Netherlands, 8 from Osaka City, and 2 from
GenBank). Sequence comparison showed 91.5% nucleotide
and97.4% amino acid identities among these Melksham-like
strains. A total of 301 nucleotide changes were observed (Ta-
ble 5), the majority of which were third-base changes (87%)
and synonymous (88.7%). These nucleotide changes resulted
in amino acid changes in 32 codons, half of which were located
in the P2 subdomain. Twelve of 32 amino acid positions were
informative (9 in the P2 subdomain) (Fig. 3). In contrast with
the previous finding, several mutations were fixed: of the 12
informative sites, 2 amino acid substitutions (amino acid posi-
tions 245 and 440) in the P1 subdomain and 3 amino acid
substitutions (amino acid positions 342, 344, and 345) in P2
subdomain were cumulative (Table 6), segregating the strains
into five genetic groups (1994 to 1997, 1999 to 2000, 2001 to
2003, 2004, and 2005) by the neighbor-joining method (Fig.
2A) and Bayesian method (Fig. 2B).The strains detected in the
spring epidemic in Osaka City had a unique sequence, with S
or P residues at amino acid position 364 (Fig. 3 and Table 6).
The other six informative sites were not fixed.
The 3D structure of the P domain of a monomer of the NoV
capsid protein was predicted by WHAT IF, 3D-Jigsaw, and
EsyPred3D, based on the known 3D structure of the VA387/
98/US GII.4 genotype capsid protein, which has 55% amino
acid sequence identity in the P domain to the Melksham capsid
protein. A comparison of the positions of the six fixed muta-
tions to the predicted 3D structure indicated that all six resi-
dues were predicted to be located at the surface of the capsid
protein, with three residues (342, 344, and 345) close to each
TABLE 3. The numbers of nucleotide and amino acid substitutions in the complete capsid gene among 14 GII.2 strains detected in the
spring epidemic of 2004 in Osaka City, Japan
Domain or
subdomaina
Nucleotide substitutions Amino acid substitutions
No. of
substitutions
No. at the indicated
position of the
changed codon
Synonymous
changes (no.)
Nonsynonymous
changes (no.)
No. of
substitutions
Informative
changes (no.)
1st 2nd 3rd
N 1 0 0 1 1 0 0 0
S 18 3 2 13 16 2 2 0
P1 7 0 0 7 6 1 1 0
P1-1 4 0 0 4 4 0 0 0
P1-2 3 0 0 3 2 1 1 0
P2 19 3 2 14 14 5 5 0
Total 45 6 4 35 37 8 8 0
a Each domain of GII.2 NoV capsid gene was determined according to Chen et al. (7). The region and abbreviation of each domain are as follows: N, 5 end of ORF2
and N terminal domain (residues 1 to 45); S, shell domain (residues 46 to 216); P1, P1 subdomain (P1-1, residues 217 to 274; P1-2, residues 421 to 542); P2, P2
subdomain (residues 275 to 420).
TABLE 4. The numbers of nucleotide and amino acid substitutions in the complete capsid gene among 29 GII.2 strains collected in the
GenBank, The Netherlands, and Japan over a 30-year period
Domain or
subdomaina
Nucleotide substitutions Amino acid substitutions
No. of
substitutions
No. at the indicated
position of the
changed codon
Synonymous
changes (no.)
Nonsynonymous
changes (no.)
No. of
substitutions
Informative
changes (no.)
1st 2nd 3rd
N 20 0 2 18 17 3 3 1
S 137 9 3 125 131 6 6 1
P1 162 17 7 138 143 19 16 4
P1-1 53 4 2 47 49 4 3 2
P1-2 109 13 5 91 94 15 13 2
P2 169 28 13 128 128 41 34 19
Total 488 54 25 409 419 69 59 25
a See note to Table 3.
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other in the P2 subdomain (Fig. 4). Furthermore, residues 342,
344, 345 of the P2 subdomain and residues 245 and 440 of the
P1 subdomain were grouped closely together on the predicted
3D structure of a dimer (3D-modeling by WHAT IF) (Fig. 5).
DISCUSSION
In this study, we analyzed the complete capsid gene of GII.2
NoVs collected over a 30-year period. The collection included
a relatively large sample from an epidemic that was observed
only in Japan in the spring period of 2004. In this 3-month
period, no evolutionary changes were observed, but compared
with other GII.2 Melksham-like strains these variants had
unique amino acid sequences (S or P) at position 364. One of
the recombinant genomes, strain 02022, had the same amino
acid residues, suggesting that the presence of this mutation was
not causally related to the epidemic pattern. The sequence
analysis confirmed that the spring epidemic was an outbreak.
Molecular characterization of the GII.2 capsids over the full
study period showed an interesting difference between recom-
binant genomes and nonrecombinant (Melksham-like) ge-
nomes. The Melksham-like strains clearly evolved over time,
with accumulation of mutations particularly in the P2 subdo-
main. In contrast, GII.2 capsids from recombinant genomes
did not fit this pattern and had a seemingly erratic pattern of
mutations. Melksham-like strains are occasionally observed in
molecular surveillance data from The Netherlands and Osaka
FIG. 3. Amino acid alignment of the P2 subdomains of GII.2 NoV strains showing mutations along the aligned sequences. The upper sequence
alignment group (A) includes the Melksham-like strains and the lower group (B)includes the other GII.2 strains, which were recombinant genomes. In
each group, sequences are arranged chronologically from top (oldest) to bottom (most recent). The detection years of the strains are indicated in
parentheses. The asterisk indicates informative sites among Melksham-like strains. The arrow denotes cumulatively changing amino acid positions (342,
344, and 345) among Melksham-like strains. The numbers above the sequences indicate the sequence position relative to the position in the capsid protein
of strain Melksham. Underlined sequences indicate the KGE motif that corresponds to the RGD-like motif of other NoVs and was determined with the
amino acid sequence alignment of other NoVs according to Tan et al. (34). For strain abbreviations, see Table 1.
TABLE 5. The numbers of nucleotide and amino acid substitutions in the complete capsid gene among 20 Melksham-like
strains over a 12-year period
Domain or
subdomaina
Nucleotide substitutions Amino acid substitutions
No. of
substitutions
No. at the indicated
position of the
changed codon
Synonymous
changes (no.)
Nonsynonymous
changes (no.)
No. of
substitutions
Informative
changes (no.)
1st 2nd 3rd
N 10 0 2 8 8 2 2 0
S 81 4 3 74 76 5 6 1
P1 98 8 3 87 89 9 8 2
P1-1 34 2 1 31 32 2 2 1
P1-2 64 6 2 56 57 7 6 1
P2 112 13 6 93 94 18 16 9
Total 301 25 14 262 267 34 32 12
a See note to Table 3.
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City, and strains from Japan and The Netherlands could be
consistently grouped in the same alignment, suggesting contin-
uous widespread circulation and an ability to cause disease.
The recombinant genomes with GII.2 capsids, however, occur
sporadically and did not show evidence for evolution, suggest-
ing that their circulation is limited (1, 4, 17). The finding that
strains from such widely separated geographic regions were
similar shows that evolution of GII.2 NoVs is a global phe-
TABLE 6. Amino acid substitutions at six positions in the P domain among Melksham-like strains
Strain description
Amino acid and codon at the indicated position of the capsid proteina
245 342 344 345 364 440
Nameb Countryc Detection date(mo/day/yr) Residue Codon Residue Codon Residue Codon Residue Codon Residue Codon Residue Codon
Melksham UK 1994 P CCC Q CAG A GCC A GCT A GCA L CTC
CF434 US 1997 — CCC — CAG — GCT — GCT — GCA — CTT
S99-191 NL 1/1999 S TCT — CAA — GCC T ACT — GCA I ATC
OB0037 NL 9/2000 S TCT — CAA — GCC T ACT — GCA I ATC
OB0048 NL 12/2000 S TCT — CAA — GCC T ACT — GCA I ATC
OB0115 NL 2/2001 S TCT H CAC — GCC S TCT — GCA I ATC
EP0125 NL 11/2001 S TCC H CAC — GCC S TCT — GCA I ATC
02012 JP 1/2002 S TCC H CAC — GCC S TCT — GCA I ATC
EP0207 NL 1/2002 S TCC H CAC — GCC S TCT — GCA I ATC
EP0239 NL 2/2002 S TCC H CAC — GCC S TCT — GCA I ATC
OB0371 NL 10/2003 S TCC H CAC — GCC S TCT — GCA I ATC
04038 JP 3/11/2004 S TCC H CAC S TCC P CCT S TCA I ATC
04059 JP 4/18–30/2004 S TCC H CAC S TCC P CCT S TCA I ATC
S040035 JP 4/21/2004 S TCC H CAC S TCC P CCT S TCA I ATC
04071 JP 5/16–23/2004 S TCC H CAC S TCC P CCT P CCA I ATC
04073 JP 5/22/2004 S TCC H CAC S TCC P CCT S TCA I ATC
04075 JP 5/25/2004 S TCC H CAC S TCC P CCT S TCA I ATC
S040100 JP 5/31/2004 S TCC H CAC S TCC P CCT S TCA I ATC
OB0528 NL 1/2005 S TCC H CAC S AGC P CCT — GCA I ATT
OB0587 NL 4/2005 S TCC H CAC S AGC P CCT — GCA I ATT
a The position number corresponds to the capsid sequence of the Melksham/94/UK strain; a dash indicates sequence identity with this strain. Residues are indicated
by their single-letter codes.
b For strain abbreviations, see Table 1.
c UK, United Kingdom; US, United States; NL, The Netherlands; JP, Japan.
FIG. 4. Location of six fixed amino acid residues (positions 245, 342, 344, 345, 364, and 440, shown in red) on the monomer of the capsid
protein. This 3D structure for the monomer P domain of the GII.2 NoV capsid protein was made by WHAT IF. The P1 and P2 subdomains are
shown in blue and gray, respectively. The S domain is not shown. The KGE motif in the P2 domain is shown in green. (A) Predicted location of
amino acid residues 342, 344, 345, and 364 in the P2 subdomain. (B) A view identical to panel A rotated 180° horizontally showing the location
of amino acid residues 245 and 440 in the P1 subdomain.
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nomenon, similar to what has been described for GII.4 NoVs
(5, 27, 33).
The molecular characterization of Melksham-like strains
showed accumulation of mutations over a 12-year period, seg-
regating them into five genetic groups. Three of these were
supported in phylogenetic analysis with high bootstrap values.
Two others (Fig. 2, 1999 to 2000 and 2001 to 2003) were not
distinguishable in phylogenetic analysis, possibly because of
the small number of isolates in the comparison. The present
collection, however, contains all GII.2 strains detected in the
two countries in the past 12 years of surveillance. Amino acid
position 345 was the most variable in all GII.2 strains. This is
suggestive of immune pressure, particularly because the amino
acid is predicted to be located on a surface-exposed part of the
capsid. The fixed amino acid changes were topologically clus-
tered, judging from the 3D structure prediction, indicating that
combined they may form an epitope. Immunity to NoVs has
not been studied very systematically, but recent work on GII.4
NoVs has suggested that these viruses evolved under immune
pressure (9, 30, 33). The lack of a tissue culture model makes
it difficult to corroborate these findings by using cross-neutral-
ization tests with hyperimmune serum directed against specific
variants. Evolution of strains in an immunocompromised pa-
tient with chronic shedding of NoVs has been demonstrated by
Nilsson et al. (28), who suggested that the cumulative amino
acid substitutions appearing in the P2 subdomain were im-
mune response driven. To clarify the relations between these
amino acid mutations and receptor or antibody binding further
immunological studies are needed.
Recently, new variants of the predominant NoV, the GII.4
genotype, appeared in 2002 (27), 2004 to 2005 (5), and 2006
(33) with global distribution. These new GII.4 variants were
characterized into different clusters by the phylogenetic anal-
ysis based on the capsid gene (5, 9, 30). Okada et al. (30)
reported that GII.4 strains had cumulative amino acid changes
in the P domain and 5% to 18% amino acid diversity in the P2
subdomain between GII.4 subtypes for 5 years study. Bull et al.
(5) also described more than 5% amino acid diversity in the
complete capsid gene between past GII.4 strains and variants.
Siebenga et al. (33) found 9% fixed amino acid mutations
across the capsid gene over a 12-year period, but only five of
these consistently delineated subsequent epidemic strains. In
contrast, here we found only 2.6% amino acid diversity across
the complete capsid gene of Melksham-like strains in a 12-year
period, showing a clearly lower rate of change. The difference
between these genotypes is intriguing and suggests clear dif-
ferences in epidemiology that are not easy to explain. This
study has been done using a limited number of strains in a rare
genotype from a limited number of locations. It is necessary to
FIG. 5. The 3D structure of a dimer of the GII.2 NoV capsid protein, as predicted by WHAT IF, showing the location of the six informative
amino acid residues (red). Monomer A is shown in yellow, while the monomer B is shown in blue (P1) and gray (P2). The S domains are not shown.
The KGE motif (green) in the P2 subdomain on monomer B is also shown.
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continue molecular surveillance of NoV infections to further
the evolutional analysis of each genotype.
In conclusion, the present study showed that NoVs belonging
to a rare genotype evolved by the accumulation of mutations in
the surface-exposed parts of the capsid, suggesting immune re-
sponse-driven evolution. The pattern of change similar to what
has been observed for GII.4 is a global one, suggesting that these
viruses circulate much more than is apparent from their presence
in surveillance data. The data also showed for the first time that
recombinant genomes of NoVs behave differently, even when
they share the same capsid genes as nonrecombinant genomes.
Understanding how NoVs evolve is necessary for finding more
effective ways to control this disease and particularly its impact in
healthcare settings.
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